Prevalence and incidence of pseudomyxoma peritonei in urban China: A nationwide retrospective cohort study

• DOI: 10.1016/j.ejso.2022.06.013
• Publication Date: 2022-06-11T09:07:43Z
• Authors: Jing-Nan Feng; A-Jin Hu; Lu Xu; Li-Li Liu; Guo-Zhen Liu; Jin-Xi Wang; Pei Gao; Cong-Rong Liu; Sheng-Feng Wang; Si-Yan Zhan
• Keywords: Male; Adult; Aged, 80 and over; China; Adolescent; Incidence; Pseudomyxoma Peritonei; 3. Good health; Young Adult; Prevalence; Humans; Female; Peritoneal Neoplasms; Retrospective Studies

Pseudomyxoma peritonei (PMP) is an extremely rare condition. Information regarding the disease burden of PMP in developing countries is limited. This study aimed to determine the epidemiology of PMP in China.PMP data were extracted from the national databases of Urban Basic Medical Insurance. All cases were identified using the International Classification of Diseases (ICD) codes and Chinese diagnostic terms. The national prevalence from 2012 to 2016 and incidence in 2016 were estimated.In total, 153 patients with PMP were identified. The crude prevalence of PMP in 2016 was 2.47 (95% confidence interval [CI] 1.71 to 3.23) per million person-year, with a higher prevalence in females than males. Prevalence increased with age, with the first peak in those aged 15-29 years and the highest in those aged >80 years. The crude incidence of PMP in 2016 was 1.19 (95% CI 0.59 to 1.78) per million person-years. Similar to the prevalence, the rates were higher in women than in men. The incidence also increased with age, with the highest prevalence in those aged >80 years. Besides, the most frequent comorbidities before and after the first diagnosis of PMP were unspecified secondary malignancies and malignancies of unspecified sites, followed by abdominal malignant tumours.The rate of PMP was lower in mainland China than in European countries and increased with advancing age. Women were more likely to have PMP than men. Furthermore, an insufficient understanding of this rare disease presents a major challenge in accurately evaluating the disease burden.